| LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 |
1399 NEW YORK AVENUE NW
| Address2 |
SUITE 300
|
| City |
WASHINGTON
| State |
DC
| Zip Code |
20005
| Country |
USA
|
3. Principal place of business (if different than line 2)
| City |
| State |
| Zip Code |
| Country |
|
| 5. Senate ID# 15920-12
|
||||||||
| 6. House ID# 314640000
|
||||||||
| TYPE OF REPORT | 8. Year |
2012
| Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
| 11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
| Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature |
Digitally Signed By: Shannon Steward
| Date |
10/18/2012 1:08:24 PM
|
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY13 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs, hepatitis screeinng, care and treatmen, and access to breast cancer treatment.;Following issues related to the budget and appropriations process FY 13 appropriations for FDA as awell as the potential outcomes for negotiations on altering sequestration targets via legislation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Darin
|
Gardner
|
|
Director
| |
|
Evan
|
Morris
|
|
Vice President
| |
|
Eli
|
Kogan
|
|
Assoc. Director
| |
|
David
|
Burt
|
|
Director
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
TAX Monitoring proposals on US tax treatment of foreign-owned US Corporations; general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations.Research and Development Tax credit, alternative sales pricing; R&D Tax Credit (H.R. 942) FDA Appropriations, PDUFA Reauthorization; Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R & D tax credit. S.3521, Family and Business Tax Cut Certainty Act of 2012 (tax extenders). Corporate tax reform issues (no specific legislation)
Implementation of healthcare reform law. FDA drug approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. PDUFA reauthorization. FY13 appropriations bills, including issues related to FDA funding and drug approval/review oversight process. Legislation related to altering sequestration targets. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R & D tax credit. S.3521, Family and Business Tax Cut Certainty Act of 2012 (tax extenders). Corporate tax reform issues (no specific legislation)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Evan
|
Morris
|
|
Vice President
| |
|
Darin
|
Gardner
|
|
Director
| |
|
Katherine
|
Martin
|
|
Director
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
MMM: implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues related to the PPS rule involving stroke guidelines. Proposals to reduce Medicare payment for Part B biologics. Concerns regarding Medicare payment policies for Biologics; Monitor implementation of Medicare pharmaceutical coverage and reimbursement and 340B provisions of the Affordable Care Act; Proposed cuts to Part B reimbursement
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Katherine
|
Martin
|
|
Director
| |
|
David
|
Burt
|
|
Director
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of healthcare reform law. FDA drug approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. PDUFA reauthorization; FY12 Labor HHA Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 3630, A bill to exten the payroll tax holiday and for other purposes; Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Legislation on public health preparedness and response related to pandemic influenza. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Affordable Care Act Health reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement: Legislation for CMS
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Evan
|
Morris
|
|
Vice President
| |
|
Darin
|
Gardner
|
|
Sr. Director
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Cyber security, Implementation of S.23: America Invents Act, Implementation of HR 1249: Leahy-Smith America Invents Act., Transpacific partnership
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Darin
|
Gardner
|
|
Sr. Director
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
PHA: proposed cuts to Part B reimbursement. 340b reimbursement policy;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
|
Darin
|
Gardner
|
|
Sr. Director
| |
|
Katherine
|
Martin
|
|
Director
| |
|
David
|
Burt
|
|
Director
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
| State |
| Zip Code |
| Country |
|
21. Client new principal place of business (if different than line 20)
| City |
| State |
| Zip Code |
| Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
| 3 |
|
||||||
| 2 |
| 4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
|
||||||||||||||
|
|
|
|||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address | Principal place of business (city and state or country) | Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
|
||||||||||||||
|
|
| % | ||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |